Are you Dr. Catchatourian?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 35 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1900 W Polk St
Suite 751
Chicago, IL 60612Phone+1 312-854-7257Fax+1 312-864-9002
Summary
- Dr. Rosalind Catchatourian, MD is an oncologist in Chicago, Illinois. She is currently licensed to practice medicine in Illinois and California. She is affiliated with Rush University Medical Center.
Education & Training
- University of Illinois College of Medicine at ChicagoFellowship, Hematology and Medical Oncology, 1972 - 1975
- University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1970 - 1972
- West Suburban Medical CenterInternship, Transitional Year, 1969 - 1969
- National Taiwan University College of MedicineClass of 1967
Certifications & Licensure
- CA State Medical License 1975 - Present
- IL State Medical License 1972 - 2020
Clinical Trials
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 12
- S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Start of enrollment: 2008 Dec 01
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Publications & Presentations
PubMed
- 52 citationsA randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.John Mascarenhas, Heidi E Kosiorek, Josef T Prchal, Alessandro Rambaldi, Dmitriy Berenzon
Blood. 2022-05-12 - 120 citationsPegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyureaAbdulraheem Yacoub, John Mascarenhas, Heidi E. Kosiorek, Josef T. Prchal, Dmitriy Berenzon
Blood. 2019-10-31 - 20 citationsA prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.John Mascarenhas, Heidi E. Kosiorek, J. T. Prchal, Abdulraheem Yacoub, Dmitriy Berenzon
Leukemia. 2019-07-30
Professional Memberships
- Member